Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
about
Dialysis-associated hypertension treated with Telmisartan--DiaTel: a pilot, placebo-controlled, cross-over, randomized trialAngiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway.Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cellsCardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.Development of telmisartan in the therapy of spinal cord injury: pre-clinical study in rats.Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage.Treating the metabolic syndrome.Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients.Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?Preoperative treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker has no beneficial effect on the development of new-onset atrial fibrillation after off-pump coronary artery bypass graft surgery.Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers.
P2860
Q28535223-9BE87AC6-9AAE-41EF-BA80-0AE2C408254AQ34115852-D13A3E84-AA2D-4BBF-811E-98D8EA991441Q35168375-69BB5BE5-5853-4589-98EF-66E89AF78F42Q35216408-2DA3D3EE-66CD-4198-9249-C5BC138551BAQ35981368-E05C78C5-95D8-435C-8FED-08AF70A6FF47Q36242608-303344E0-3FAD-45B8-B5CE-535BCED48734Q36752058-E8B49ECB-DDBF-4332-A6A5-165633DAEDAAQ36815978-1282BFBF-0D59-4384-A33D-87C10D6B09F6Q37663578-3E88C779-C69B-411C-A23A-1C8749A59735Q37671457-D73AEEDC-13D0-4EDE-9638-46EC15B5C69FQ44952251-E1A52B34-935E-4DA1-9F7D-F0CAC0A94B28Q47103746-DF6582B2-5C43-4256-A2D6-5F7361A511D8
P2860
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Hypertension mega-trials with ...... angiotensin receptor blockers.
@ast
Hypertension mega-trials with ...... angiotensin receptor blockers.
@en
type
label
Hypertension mega-trials with ...... angiotensin receptor blockers.
@ast
Hypertension mega-trials with ...... angiotensin receptor blockers.
@en
prefLabel
Hypertension mega-trials with ...... angiotensin receptor blockers.
@ast
Hypertension mega-trials with ...... angiotensin receptor blockers.
@en
P1476
Hypertension mega-trials with ...... angiotensin receptor blockers.
@en
P2093
Stevo Julius
P304
P356
10.1016/J.AHJ.2004.04.037
P407
P577
2004-11-01T00:00:00Z